Results 131 to 140 of about 3,260 (145)
Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review
Blood and Lymphatic Cancer: Targets and Therapy, 2023 Nada Alsuhebany,1– 3 Congshan Pan,4 Eileen Holovac,5 Brian Do,6 Ali McBride7 1College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia; 2King Abdulaziz Medical City, National Guard Health Affairs ...
Nada Alsuhebany
exaly +1 more source
Leukemia and Lymphoma, 2020 The pharmacokinetics and safety of single-dose zanubrutinib (80 mg) were assessed in subjects with mild, moderate, and severe hepatic impairment (n = 6 each, Child-Pugh class A, B, and C) relative to healthy controls (n = 11).
Srikumar Sahasranaman +2 more
exaly +2 more sources
A Phase III Study of Zanubrutinib Plus Rituximab Versus Bendamustine Plus Rituximab in Transplant-Ineligible, Untreated Mantle Cell Lymphoma [PDF]
Future Oncology, 2021 Mantle cell lymphoma is an aggressive B-cell malignancy. Current frontline chemoimmunotherapies produce high response rates but relapse is inevitable.
Marco Ladetto +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Disseminated fungal infection in a patient receiving zanubrutinib
Clinical Case Reports (discontinued), 2023Zuhair K Ballas +2 more
exaly